WO2006030322A3 - Use of fla vone/fla vanone derivatives fn the treatment or prevention of respiratory conditions - Google Patents

Use of fla vone/fla vanone derivatives fn the treatment or prevention of respiratory conditions Download PDF

Info

Publication number
WO2006030322A3
WO2006030322A3 PCT/IB2005/003591 IB2005003591W WO2006030322A3 WO 2006030322 A3 WO2006030322 A3 WO 2006030322A3 IB 2005003591 W IB2005003591 W IB 2005003591W WO 2006030322 A3 WO2006030322 A3 WO 2006030322A3
Authority
WO
WIPO (PCT)
Prior art keywords
fla
treatment
prevention
vanone
vone
Prior art date
Application number
PCT/IB2005/003591
Other languages
French (fr)
Other versions
WO2006030322A2 (en
Inventor
Edwin A Kroeger
Original Assignee
Univ Manitoba
Edwin A Kroeger
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Manitoba, Edwin A Kroeger filed Critical Univ Manitoba
Publication of WO2006030322A2 publication Critical patent/WO2006030322A2/en
Publication of WO2006030322A3 publication Critical patent/WO2006030322A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Abstract

The present invention is directed to the use of compounds of the formula I below as bronchodilators and anti-inflammatory compounds for the treatment and/or prevention of diseases of the respiratory or nasal tract by administering a therapeutically effective amount of a compound of formula I to a patient in need of such treatment. The compounds of formula I are: where R is hydroxyl, methoxy or amino; R1 is hydroxyl, methoxy or amino; R2 is hydroxyl, methoxy or amino, m is an integer from 0 to 3; n is an integer from 0 to 3; and p is an integer from 0 to 3, and the pharmaceutically acceptable salts thereof.
PCT/IB2005/003591 2004-09-17 2005-09-13 Use of fla vone/fla vanone derivatives fn the treatment or prevention of respiratory conditions WO2006030322A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US61102004P 2004-09-17 2004-09-17
US60/611,020 2004-09-17

Publications (2)

Publication Number Publication Date
WO2006030322A2 WO2006030322A2 (en) 2006-03-23
WO2006030322A3 true WO2006030322A3 (en) 2006-06-29

Family

ID=36060401

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2005/003591 WO2006030322A2 (en) 2004-09-17 2005-09-13 Use of fla vone/fla vanone derivatives fn the treatment or prevention of respiratory conditions

Country Status (1)

Country Link
WO (1) WO2006030322A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009051790A (en) * 2007-08-29 2009-03-12 Maruzen Pharmaceut Co Ltd Antioxidant, anti-aging agent, anti-inflammatory agent, hair restoration agent, anti-obesity agent, skin-lightening agent, cosmetic and food and drink for cosmetic use
CN102274237B (en) * 2011-06-16 2012-12-05 成都中医药大学 Novel application of flavonoid compound
JP5936925B2 (en) * 2012-06-04 2016-06-22 丸善製薬株式会社 Matrix metalloproteinase-2 (MMP-2) activity inhibitor, matrix metalloproteinase-9 (MMP-9) mRNA expression increase inhibitor, epidermal keratinocyte proliferation promoter, androgen receptor antagonist, hair papilla cell proliferation promoter, Endothelin-1 mRNA expression increase inhibitor and SCF mRNA expression increase inhibitor
CN107759553A (en) * 2012-10-11 2018-03-06 阿玛纶生物有限公司 New flavonoids and application thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5972995A (en) * 1997-10-16 1999-10-26 Children's Hospital Medical Center Of Northern California Compositions and methods for cystic fibrosis therapy
WO2003022994A2 (en) * 2001-09-06 2003-03-20 Synorx, Inc. Inhibition by 3-deoxyflavonoids of t-lymphocyte activation and therapies related thereto
US20040191327A1 (en) * 2003-03-24 2004-09-30 Council Of Scientific And Industrial Research Method of treating and/or preventing asthma using natural compound luteolin

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5972995A (en) * 1997-10-16 1999-10-26 Children's Hospital Medical Center Of Northern California Compositions and methods for cystic fibrosis therapy
WO2003022994A2 (en) * 2001-09-06 2003-03-20 Synorx, Inc. Inhibition by 3-deoxyflavonoids of t-lymphocyte activation and therapies related thereto
US20040191327A1 (en) * 2003-03-24 2004-09-30 Council Of Scientific And Industrial Research Method of treating and/or preventing asthma using natural compound luteolin

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
HARZEKAMP ET AL: "Isolation of a bronchodilator flavonoid from the Thai medicinal plant", J. ETHNOPHARMACOL, vol. 78, no. 1, 2001, pages 45 - 49 *
HOMMA ET AL: "Inhibitory Effect of Lignans and flavonoids in Saiboku-To, a Herbal Medicine for Bronchial Asthma, on the Release of Leukotrienes from Human Polymorphonuclear Leukocytes", PLANTA MED, vol. 66, 2000, pages 88 - 91 *
NAKAJIMA ET AL: "Inhibitory Effect of Baicalein, a Flavonoid in Scutellaria Root, on Eotaxin Production by Human Dermal Fibroblasts", PLANTA MED, vol. 67, 2001, pages 132 - 135, XP055166920, DOI: doi:10.1055/s-2001-11532 *
SOUZA ET AL: "Anti-anaphylactic and Anti-inflammatory Effects of Ternatin, a Flavonoid Isolated Egletes viscosa Less", BRAZILIAN J. MED. BIOL. RES., vol. 25, 1992, pages 1029 - 1032 *

Also Published As

Publication number Publication date
WO2006030322A2 (en) 2006-03-23

Similar Documents

Publication Publication Date Title
MY139577A (en) Anti-inflammatory androstane derivative
WO2011005811A8 (en) Combination therapy for the treatment of diabetes
ATE440603T1 (en) 8-HYDROXYQUINOLINE DERIVATIVES
DE60315674D1 (en) NEW IMIDAZOPYRIDINE AND ITS USE
EP0908182A4 (en) Preventives or remedies for diseases induced by hypofunction of nitric oxide synthase (nos)
WO2004037807A3 (en) Medicinal arylethanolamine compounds
MX2009006764A (en) Bicyclic pyrimidinones and uses thereof.
UA85708C2 (en) Benzoxazine-containing pharmaceutical combinations for treating respiratory tract diseases
NO20055565L (en) Use of derivatives of 2,4-dihydro- [1,2,4] triazol-3-thione as inhibitors of the enzyme myeloperoxidase (MPO)
IL160028A (en) Thiophene carboxamide derivatives, process for their preparation, pharmaceutical compositions comprising them and their use in therapy
WO2004045618A3 (en) Novel medicaments for the treatment of chronic obstructive pulmonary diseases
WO2006081431A3 (en) Compounds for treating inflammatory and demyelinating diseases
WO2005115470A3 (en) PHARMACEUTICAL COMPOSITIONS COMPRISING β-CARBOLINE DERIVATIVES AND USE THEREOF FOR THE TREATMENT OF CANCER
WO2005044192A3 (en) Triazole compounds and uses related thereto
EP1400529A4 (en) Glucopyranosyloxypyrazole derivative, medicinal composition containing the same, medicinal use thereof, and intermediate therefor
WO2004037789A8 (en) Methylene urea derivatives as raf-kinase inhibitors
WO2008022189A3 (en) Administration of high potency platinum compound formulations by inhalation
WO2008009210A8 (en) Optical pure dihydropyrimidine compounds, their uses in the manufacture of a medicamnent for the treatment or the prevention of virosis diseases
WO2006030322A3 (en) Use of fla vone/fla vanone derivatives fn the treatment or prevention of respiratory conditions
EA200800071A1 (en) DERIVATIVES OF BENZOFURANILA AS AN INHIBITORS OF 5-НТ6-RECEPTOR
CY1109546T1 (en) MEDICINE FOR PREVENTION OR TREATMENT OF FREQUENCY
TW200635592A (en) Pyridyl-substituted spiro-hydantoin compounds and use thereof
WO2002026732A1 (en) Benzodiazepine derivative
BRPI0513549A (en) pharmaceutical compositions for the treatment of leishmaniasis
WO2007092436A3 (en) Compounds for treating inflammatory disorders, demyelinating disorders and cancers

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

NENP Non-entry into the national phase

Ref country code: DE

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase

Ref document number: 05803652

Country of ref document: EP

Kind code of ref document: A2